Athira pharma reports second quarter 2024 financial results and pipeline and business updates

Topline data from completed phase 2/3 lift-ad clinical trial of fosgonimeton as a potential treatment for mild-to-moderate alzheimer's disease targeted for september 2024 phase 2/3 lift-ad data to be presented in an oral presentation at ctad in october 2024 phase 1 clinical trial of ath-1105 underway for the potential treatment of amyotrophic lateral sclerosis (als) bothell, wash., aug. 01, 2024 (globe newswire) -- athira pharma, inc. (nasdaq: atha), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended june 30, 2024, and provided recent pipeline and business updates.
ATHA Ratings Summary
ATHA Quant Ranking